AUA 2025: Focus on Bladder Cancer
Advertisement
Dr. Brown breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG.
Results of the CREST study show that sasanlimab plus BCG improves EFS compared with BCG alone in high-risk NMIBC.
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC.
Global shortages of BCG have led to the exploration of alternative therapies for HR non-muscle invasive bladder cancer.
Consolidative surgery after EVP shows feasibility and strong pathologic response rates in advanced urothelial carcinoma.
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
Interim data may support the use of light-activated TLD-1433 photodynamic therapy for patients with BCG–unresponsive NMIBC.
N-803 plus BCG delivers sustained complete responses and high PFS in BCG-unresponsive bladder CIS, 2025 AUA data show.
Dr. Roberto Contieri presented on the safety, tolerability, and efficacy of neoadjuvant mitomycin C in patients with NMIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.